These authors contributed equally to this work.
Positron Emission Tomography Imaging of Drug-Induced Tumor Apoptosis with a Caspase-Triggered Nanoaggregation Probe†
Article first published online: 23 JUL 2013
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 52, Issue 40, pages 10511–10514, September 27, 2013
How to Cite
Shen, B., Jeon, J., Palner, M., Ye, D., Shuhendler, A., Chin, F. T. and Rao, J. (2013), Positron Emission Tomography Imaging of Drug-Induced Tumor Apoptosis with a Caspase-Triggered Nanoaggregation Probe . Angew. Chem. Int. Ed., 52: 10511–10514. doi: 10.1002/anie.201303422
This work has been supported by the Stanford University National Cancer Institute (NCI) Centers of Cancer Nanotechnology Excellence (grant number 1U54CA151459-01), the NCI ICMIC@Stanford (grant number 1P50CA114747-06), and an IDEA award from the Department of Defense Breast Cancer Research Program (grant number W81XWH-09-1-0057). M.P. is grateful to the postdoctoral fellowship support from the Danish Cancer Foundation, and A.S. is supported by a postdoctoral fellowship from the Susan Komen Breast Cancer Foundation. The use of Stanford Small Animal Imaging Facility is acknowledged.
- Issue published online: 23 SEP 2013
- Article first published online: 23 JUL 2013
- Manuscript Received: 23 APR 2013
- National Cancer Institute. Grant Numbers: 1U54CA151459-01, 1P50CA114747-06
- Department of Defense Breast Cancer Research Program. Grant Number: W81XWH-09-1-0057
- drug design;
- positron emission tomography
Drug Design: An 18F-labeled caspase-3-sensitive nanoaggregation positron emission tomography tracer was prepared and evaluated for imaging the caspase-3 activity in doxorubicin-treated tumor xenografts. Enhanced retention of the 18F activity in apoptotic tumors is achieved through intramolecular macrocyclization and in situ aggregation upon caspase-3 activation (see picture).